Farmington, CT, November 8, 2022 – CaroGen Corporation (https://carogencorp.com), a developer of transformative immunotherapies for cancer and infectious diseases, today announced that new preclinical data about the mechanism of action of CaroGen’s novel ovarian cancer immunotherapy, CARG-2020,